Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARγ/PTEN/mTOR signaling pathway

Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARγ/PTEN/mTOR signaling pathway

Abstract Background Thirty to 40 % of non-small cell lung cancer (NSCLC) patients developed higher hypertriglyceridemia in the process of treatment with bexarotene. And bioinformatics studies discovered that the expression of slc10a2 was increased in high-grade hypertriglyceridemia patients. So, we...

Full description

Bibliographic Details
Main Authors: Xinghao Ai, Feng Mao, Shengping Shen, Yang Shentu, Jiejun Wang, Shun Lu
Format: Article
Language:English
Published: BMC 2018-04-01
Series:BMC Cancer
Subjects:
Non-small cell lung cancer
A549 cells
H1299 cells
Bexarotene
slc10a2
PPARγ
Online Access:http://link.springer.com/article/10.1186/s12885-018-4224-x

Internet

http://link.springer.com/article/10.1186/s12885-018-4224-x

Similar Items